Drug-herb interactions between Scutellaria baicalensis and pharmaceutical drugs: Insights from experimental studies, mechanistic actions to clinical applications - 16/04/21
, Ling Fu b, c, d, Pengli Wang b, e, Lan Yang b, e, Xiaoshu Zhu b, Chun Guang Li a, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 18 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Whilst the popular use of herbal medicine globally, it poses challenges in managing potential drug-herb interaction. There are two folds of the drug-herb interaction, a beneficial interaction that may improve therapeutic outcome and minimise the toxicity of drug desirably; by contrast, negative interaction may evoke unwanted clinical consequences, especially with drugs of narrow therapeutic index.
Scutellaria baicalensis Georgi is one of the most popular medicinal plants used in Asian countries. It has been widely used for treating various diseases and conditions such as cancer, diabetes, inflammation, and oxidative stress. Studies on its extract and bioactive compounds have shown pharmacodynamic and pharmacokinetic interactions with a wide range of pharmaceutical drugs as evidenced by plenty of in vitro, in vivo and clinical studies. Notably, S. baicalensis and its bioactives including baicalein, baicalin and wogonin exhibited synergistic interactions with many pharmaceutical drugs to enhance their efficacy, reduce toxicity or overcome drug resistance to combat complex diseases such as cancer, diabetes and infectious diseases. On the other hand, S. baicalensis and its bioactives also affected the pharmacokinetic profile of many drugs in absorption, distribution, metabolism and elimination via the regulatory actions of the efflux pumps and cytochrome P450 enzymes. This review provides comprehensive references of the observed pharmacodynamic and pharmacokinetic drug interactions of Scutellaria baicalensis and its bioactives. We have elucidated the interaction with detailed mechanistic actions, identified the knowledge gaps for future research and potential clinical implications. Such knowledge is important for the practice of both conventional and complementary medicines, and it is essential to ensure the safe use of related herbal medicines. The review may be of great interest to practitioners, consumers, clinicians who require comprehensive information on the possible drug interactions with S. baicalensis and its bioactives.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | S. baicalensis promoted the anti-cancer effect of cisplatin and fluorouracil. |
• | Baicalein enhanced anti-diabetic activity of metformin. |
• | Baicalein and baicalin sensitised the anti-bacterial effect of many antibiotics. |
• | S. baicalensis affected pharmacokinetic profiles of numerous pharmaceutical drugs. |
Keywords : Scutellaria baicalensis Georgi, Drug-herb interaction, Cancer, Diabetes, CYP, P-gp
Plan
Vol 138
Article 111445- juin 2021 Retour au numéro
Article précédent
- CXCL8 chemokine in ulcerative colitis
- Yunfei Zhu, Shihua Yang, Nan Zhao, Chuanguo Liu, Fayan Zhang, Yuting Guo, Huimin Liu
- Research progress on the pharmacological effect and clinical application of Tongqiao Huoxue Decoction in the treatment of ischaemic stroke
- Qiang Zhang, Lijuan Zhang, Yu Liu, Xu Tian, Xiuyang Li, Bingbing Han, Yanan Zhang, Zhichun Wu, Huayun Yu, Haijun Zhao, Shijun Wang, Ke Ma, Yuan Wang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?